INBX

Inhibrx Biosciences, Inc. · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-03-19

Figures on this page computed 2026-11-08 12:48 UTC

Last close

86.76USD

Market data, 2026-11-04

Except where said otherwise: 10-K for 2025, filed 2026-03-19

n/aP/E
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0002007919-26-000006
Reported in
USD
- computed
- 10-K for 2025, filed 2026-03-19
The filing itself
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0002007919-26-000006
Reported in
USD
- 10-K for 2025, filed 2026-03-19
- 10-K for 2025, filed 2026-03-19
- 10-K for 2025, filed 2026-03-19
- 10-Q for 2025, filed 2026-08-13
- 10-K for 2025, filed 2026-03-19
- 10-Q for 2025, filed 2026-08-13
The filing itself
-10773.5%Net margin
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0002007919-26-000006
Reported in
USD
- 10-K for 2025, filed 2026-03-19
- 10-K for 2025, filed 2026-03-19
The filing itself
-9986.5%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0002007919-26-000006
Reported in
USD
- 10-K for 2025, filed 2026-03-19
- 10-K for 2025, filed 2026-03-19
The filing itself
13.39Debt/equity
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0002007919-26-000006
Reported in
USD
- 10-K for 2025, filed 2026-03-19
- 10-Q for 2025, filed 2026-08-13
The filing itself
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Growth is the furthest below its sector's middle: 0.08 against 0.50 on the market's range.

What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Five bars, one line

lens 7 of 9

0.22x

-1.57x

1.50x

1.47x

2.52x

SalesProfitFree cash flowDebtPrice

Each bar against this company's own average; the line is that average.

Filed2025

Market data2026-11-04

Each against its own average

5 of 5 read

Except where said otherwise: 10-K for 2025, filed 2026-03-19

Sales0.22x
Its own average over 10 years, 5.8M.
Profit-1.57x
Its own average over 10 years, 89.3M.
Free cash flow1.50x
Its own average over 10 years, -86.8M.
Debt1.47x
Its own average over 10 years, 72.7M.
Price2.52x
Its own average over 7 years, 34. Market data, 2026-11-04

Profit is furthest from its own average, at -1.57 times.

Sales is 0.22 times its own 10-year average; Profit is -1.57 times its own 10-year average; Free cash flow is 1.50 times its own 10-year average; Debt is 1.47 times its own 10-year average; Price is 2.52 times its own 7-year average.

Every figure in this lens

Except where said otherwise: 10-K for 2025, filed 2026-03-19

Sales against its own 10-year average0.22
Source
filed
Statement
income
Fiscal year
2025
Accession
0002007919-26-000006
Reported in
USD
The filing itself
Profit against its own 10-year average-1.57
Source
filed
Statement
income
Fiscal year
2025
Accession
0002007919-26-000006
Reported in
USD
The filing itself
Free cash flow against its own 10-year average1.50
Source
filed
Statement
income
Fiscal year
2025
Accession
0002007919-26-000006
Reported in
USD
The filing itself
Debt against its own 10-year average1.47
Source
filed
Statement
income
Fiscal year
2025
Accession
0002007919-26-000006
Reported in
USD
The filing itself
Price against its own 7-year average2.52Market data, 2026-11-04
Source
market
Taken on
2026-11-04
Reported in
USD